Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study

British Journal of Cancer

Volumn 94, Issue 4, 2006, Pages 481-485

  Demols, A ^a   Peeters, M ^b   Polus, M ^c   Marechal, R ^a   Gay, F ^a   Monsaert, E ^b   Hendlisz, A ^d   Van Laethem, J L ^a  

^a ERASME HOSPITAL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c CHU SART TILMAN   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

Advanced and metastatic pancreatic cancer; Gemcitabine plus oxaliplatin; Second line chemotherapy

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CAPECITABINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG TOLERABILITY; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33344468699     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602966     Document Type: Article

References (18)

1. Androulakis N, Syrigos K, Polyzos A, Aravantinos G, Stathopoulos GP, Mallas K, Vamvakas L, Georgoulis V (2005) Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 23(1): 9-12
2. Blaszkowsky LS, Hulke KH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, Lawrence C, Fuchs CS (2005) A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005: abstract 4099
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
4. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44(2): 117-123
5. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Stoffregen C, Clemens M (2003) A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003 abstract 1003
6. Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20(6): 1512-1518
7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15): 3509-3516
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au K, Ding J, Christy-Bittel J, Parulekar W (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol 2005: abstract 1
9. Ng M, Norman AR, Cunningham D, Waters J, Oates J, Ross P (2005) Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy. Proc Am Soc Clin Oncol 2005: abstract 4229
10. Oettle H, Arnold D, Esser M, Huhn D, Riess H (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11(8): 635-638
11. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B, Riess H (2005) Oxaliplatin/folinic acid/5-fluorouracil (24 h) (OFF) plus best supportive care versus best supportive care alone (BSC) in second line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc Am Soc Clin Oncol 2005: abstract 4031
12. O'Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, Tchekmedyian NS, Ackerman J, De Jager RL, Eckhardt G (2004) A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2004: abstract 4006
13. Richards DA, Kindler HL, Oettle H, Ramanathan RK, Van Laethem J-L, Peeters M, Fuchs M, John W, Arning M, Von Hoff D (2004) A randomized phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Proc Am Soc Clin Oncol 2004: abstract 4007
14. Rocha Lima CMS, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22(18): 3376-3383
15. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18): 3402-3408
16. Therasse P, Arbuch SG, Eisenhower EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
17. Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopteridis P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E (2005) Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 23(4): 369-375
18. Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2003) Irinotecan plus ralitrexed vs ralitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88(8): 1180-1184